Generalized candidemia in a patient post COVID- 19 - the differential diagnosis
Keywords:
COVID-19, candidemiaAbstract
The clinical case of a 74-year-old patient with severe pancytopenia, which appeared after infection with SARS-CoV2, was described. The given case is of interest due to the difficulty of establishing the diagnosis and the severity of the evolution of the disease. Pancytopenia appeared during the course of suffering from COVID-19 and progressed in the post-COVID-19 period during about 3 months, with the worsening of the patient’s general condition, the development of generalized candidemia, and death, despite the treatment administered. The difficulty of establishing the diagnosis in the post-COVID19 period is of interest. Candidiasis, an opportunistic fungal infection, has become more prevalent as the world continues to battle COVID-19. It is crucial to understand the pathogenesis and mechanism of virulence to shed light on disease progression, especially in co-infections. The different factors that predispose patients with COVID-19 to candidiasis, their interactions, and individual effects must be well understood to prevent the development of opportunistic co-infections that drastically decrease patients’ chances of survival.
References
1. Hernandez, JM. et al. Pancytopenia and profound neutropenia as a sequela of severe SARS-CoV-2 infection (COVID-19) with concern for bone marrow involvement. In: Open Forum Infectious Diseases: 2021: Oxford University Press US; 2021: ofab017. https://doi.org/10.1093/ofid/ofab017
2. Salgado, R.C. et al. The network interplay of interferon and Toll-like receptor signaling pathways in the antiCandida immune response. Sci. Rep. 2021, 11, 20281. https://doi.org/10.21203/rs.3.rs-279551/v1
3. Baddley, J.W. et al. Coronavirus Disease 2019-Associated Invasive Fungal Infection. Open Forum Infect. Dis. 2021, 8, ofab510. https://doi.org/10.1093/ofid/ofab510
4. Gangneux, J.P. et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study. Lancet Respir. Med. 2022, 10, 180-190.
5. Kayaaslan, B. et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to nonCOVID-19 patients. Mycoses 2021, 64, 1083-1091. https://doi.org/10.1111/myc.13332
6. Machado, M. et al. Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission. J. Fungi 2022, 8, 305. https://doi.org/10.3390/jof8030305
7. Mastrangelo, A. et al. Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021, 73, e2838-e2839. https://doi.org/10.1093/cid/ciaa1594
8. Pfaller, MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133-163. https://doi.org/10.1128/CMR.00029-06
9. Oliva, A. et al. Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19. Front. Immunol. 2021, 12, 708149. https://doi.org/10.3389/fimmu.2021.708149
10. Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 2021, 6, eabl4340.
11. Terpos E. et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47. https://doi.org/10.1002/ajh.25829
12. Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI insight. 2020; 5(10). https://doi.org/10.1172/jci.insight.137799
13. Weiskopf D. et al. Phenotype and kinetics of SARSCoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. https://doi.org/10.1126/sciimmunol.abd2071
14. Wang F. et al. Systemically comparing host immunity between survived and deceased COVID-19 patients. Cell Mol Immunol. 2020;17(8):875-7. https://doi.org/10.1038/s41423-020-0483-y
15. Sharma C. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17(12):731-48. https://doi.org/10.1038/s41584-021-00709-9
16. Martinez OM. et al. The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. Nat Med. 2020;26(12):1819-24. https://doi.org/10.1038/s41591-020-1140-9
17. Pascutti MF. et al. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Front Immunol. 2016;7:364. https://doi.org/10.3389/fimmu.2016.00364
18. Brisse E. et al. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263-80. https://doi.org/10.1016/j.cytogfr.2014.10.001
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
